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ln this paper, we summarize a few of the highlights in the
elds of epidemiology, health services research, and out-
omes research published between roughly April 2008 and
une 2009. Our overview is necessarily selective, because the
heer number of articles published in these areas over the
ast year is too large to cover within the available space.
onsequently, some excellent research in these fields might
ot be mentioned.
pidemiology
he relationship of obesity to cardiovascular risk has been
ifficult to untangle, because obesity is strongly associated
ith several classical cardiovascular risk factors. Conse-
uently, the role of obesity per se—as opposed to its known
dverse effects on blood pressure, lipids, and diabetes—has
een controversial. Several articles in the past year suggest
hat obesity does indeed exert an independent effect on
ardiovascular risk. Perhaps the most definitive examination
f the effects of obesity on health is an analysis of data from
94,576 healthy individuals drawn from 57 prospective
ohort studies (1). This study showed a strong “U-shaped”
elation between body mass index and all-cause mortality,
ith lowest mortality among participants with a body mass
ndex between 22.5 and 25.0 kg/m2. Most of the excess
ortality due to obesity was caused by cardiovascular
isease, particularly among younger participants. A prospec-
ive study of 54,783 Danes showed the cardiovascular risk of
besity was independent of traditional cardiac risk factors
nd several behavioral risk factors, including physical activ-
ty (2); the Framingham Offspring Study of 4,780 adults
howed a similar result (3). An analysis of the CRUSADE
Can Rapid Risk Stratification of Unstable Angina Patients
uppress Adverse Outcomes with Early Implementation of
he American College of Cardiology/American Heart As-
ociation Guidelines) registry demonstrated that the age of
rst myocardial infarction (MI) was inversely proportional
rom the *Stanford University School of Medicine, Stanford, California; and the
Palo Alto Veterans Affairs Medical Center, Palo Alto, California. Dr. Heidenrich isr
consultant for Boston Scientific.
Manuscript received October 20, 2009, accepted October 20, 2009.o body mass index (i.e., obese subjects had heart attacks at
ounger ages) (4). These studies underscore the important
dverse effects of obesity on cardiovascular disease.
Genome-wide association studies have become more
easible with the commercial availability of “gene chips”
ontaining a very large number of genetic markers. The
ssociation of cardiovascular disease with a marker at chro-
osome 9p21.3 was further confirmed by the Cardiogenics
onsortium of 7 case-control studies (5). However, the
omen’s Genome Health Study found little clinical value
n genotyping at chromosome 9p21.3. Despite having a
ignificant and independent association with incident car-
iovascular disease, 9p21.3 did not improve risk prediction,
s assessed either by the c-index or by newer risk reclassi-
cation measures (6).
A large genome-wide association study of stroke reported
hat a locus at 12p13 was significant (7); interestingly, there
as no association of the 9p21.3 marker with stroke in this
tudy. Another genome-wide associated study reported an
ssociation between statin-induced myopathy and variants
n the SLCO1B1 gene (8), which encodes a protein involved
n statin metabolism. Steady state warfarin dose levels were
onfirmed to be correlated with patient genotype in a large
tudy of 4,043 patients (9), but 2 independent analyses
eported that genotyping at this locus was not cost-effective
10,11). On the basis of information currently available, the
alue of any genetic markers of cardiovascular disease in
linical care is as yet unestablished.
revention
ne of the biggest developments of the past year was the
ublication of the JUPITER (Justification for the Use of
tatins in Prevention: an Intervention Trial Evaluating
osuvastatin) trial (12). In the JUPITER trial, men age 50
ears and older and women age 60 years and older with a
ow-density lipoprotein (LDL) cholesterol level below 120
g/dl and a high-sensitivity C-reactive protein level above
.0 were randomized to rosuvastatin or placebo and fol-
owed for a median of 1.9 years. Rosuvastatin therapy
educed the composite end point of confirmed cardiac
d
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Year in Health Services Research and Outcomes December 15/22, 2009:2343–51eath, MI, or stroke from 1.76% to 0.93%, a relative risk
eduction of 47% (p  0.0001). Analyses of data from the
ational Health and Nutrition Study suggest that between
.5 million (13) and 8.1 million (14) individuals meet
strict” JUPITER eligibility criteria, and several million
ore might be eligible for statin therapy if the age or other
UPITER entry criteria were relaxed. The JUPITER results
ngendered some controversy about the value of expanding
ndications for statins therapy and about the value of
igh-sensitivity C-reactive protein screening.
Expansion of statin therapy to lower-risk subjects might
educe their relative risk of cardiovascular disease yet pro-
ide less absolute risk reduction than among higher-risk
ubjects. The cost-effectiveness of prevention therapies is
enerally less favorable as they are applied to lower-risk
ubjects. Nevertheless, 2 independent cost-effectiveness
tudies suggest that statin therapy might be economically
ttractive among lower-risk individuals (15,16). An analysis
ased on data from the Heart Protection Study suggested
hat if statin therapy cost $1/day or less, it would be
ost-effective even in individuals with Framingham Risk
cores below 10% (15). A model by Pletcher et al. (16)
uggested that if statins cost $1.50/day, then it would be
ost-effective to treat even relatively low-risk patients for
rimary prevention. Both of these analyses assumed that
tatin therapy is well-tolerated and safe, even with long-
erm use. A meta-analysis of 15 randomized trials (96,840
articipants) found no excess cancer risk from statin ther-
py, but mean follow-up was only 4.4 years (17).
Recent studies also addressed the question of the LDL
evel at which drug therapy should be initiated and what
DL target to use. An analysis of the JUPITER trial
uggested that lower attained LDL levels were associated
ith better outcomes (18), but this was not a randomized
omparison of LDL targets. The PROVE-IT (Pravastatin
r Atorvastatin Evaluation and Infection Therapy) trial of
ifferent treatment intensities found that baseline LDL
evels modified the efficacy of intensive statin therapy
ompared with less-intensive statin therapy, such that only
atients with higher pre-treatment LDL levels benefitted,
nd patients with lower baseline LDL levels (especially80
g/dl) obtained no additional benefit (19).
utcomes
he comparison of outcomes after drug-eluting stent
DES) or bare-metal stent (BMS) implantation was a
ibrant cottage industry over the past year, with multiple
tudies that reported on the basis of various clinical and
dministrative datasets (20–28) (Table 1). Most studies
xamined data after the approval and marketing of DES
April 2003 in the U.S.), but a few studies compared
utcomes before and after DES became available (22,25).
ecause of the very rapid adoption of the DES, there was a Co
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December 15/22, 2009:2343–51 Year in Health Services Research and Outcomestrong selection bias for DES over BMS, with differences in
any measured clinical characteristics and presumably
any differences in unmeasured characteristics, such as
ikely adherence to antiplatelet therapy. Most studies used
ropensity score methods to control for selection bias
vident from measured clinical characteristics. These studies
enerally found lower risk for total mortality, the composite
nd point of death or MI, and MI alone for patients who
eceived DES compared with patients who received BMS
Table 1). Some, but not all, of these studies also found an
ncreased risk of MI in later follow-up. However, none of
hese studies controlled for concomitant drug therapy in
eneral or for clopidogrel use in particular. A meta-analysis
f randomized trials and observational studies (29) found
hat the DES/BMS hazard ratio for all-cause mortality was
.97 (95% confidence interval: 0.81 to 1.15) on the basis of
1 randomized trials and 0.77 (95% confidence interval:
.69 to 0.85) on the basis of 22 large observational studies.
t is notable that the point estimate of the DES/BMS
azard ratio derived from randomized studies (0.97) was
utside the confidence limits derived from the observational
tudies (95% confidence interval: 0.69 to 0.85), and vice
ersa. So despite the relative consistency of the results of
ecent observational outcomes, studies showing lower mor-
ality after DES, it is possible that this is due to consistent
onfounding and strong patient selection rather than a true
reatment effect. This possibility is strengthened by evidence
f lower mortality within 30 days of DES implantation in
ome studies (20,21) and reports of fewer admissions for
leeding after DES (26), despite more intensive antiplatelet
herapy.
conomic and Quality-of-Life Outcomes
he economic effects of clinical management strategies have
rawn increased scrutiny and have been evaluated in both
andomized trials and simulation studies. The cost-
ffectiveness of percutaneous coronary intervention (PCI)
ompared with optimal medical therapy for patients with
table angina was prospectively assessed in the COURAGE
Clinical Outcomes Utilizing Revascularization and Ag-
ressive drug Evaluation) trial (30). Medical costs were
igher over 3 years among patients randomized to PCI
$34,800 vs. $24,700), whereas survival was similar, so that
he cost-effectiveness of PCI was unfavorable ($168,000/
uality adjusted life-year [QALY] added). The cost-
ffectiveness of therapeutic hypothermia after cardiac arrest
as evaluated in a simulation model by Merchant et al. (31),
ho estimate that patients treated with hypothermia gained
.66 QALYs of survival at a net cost of $31,300, which
mplies a favorable cost-effectiveness ratio of $47,200/
ALY added. Nurse-led management of heart failure was
valuated in a randomized trial of 406 patients who lived in
arlem (32). The cost of the intervention ($2,200/patient) tas largely offset by reduced hospital stays ($2,400/patient),
o the net medical costs were not significantly different. The
ntervention patients had better quality of life, so the
ost-effectiveness of the program was favorable ($16,000/
ALY).
Improvement of patient quality of life is an important
oal of medical management and hence has been assessed in
andomized trials. Percutaneous coronary intervention im-
roved quality of life significantly compared with medical
herapy for up to 24 months in the COURAGE trial (33).
ercutaneous coronary intervention to open occluded coro-
ary arteries late after an acute myocardial infarction (AMI)
mproved patient quality of life at 4 months but not in
onger follow-up in the OAT (Occluded Artery Trial) (34).
mplantable cardioverter-defibrillator (ICD) therapy did
ot affect quality of life either for the better or the worse in
he SCD-HEFT (Sudden Cardiac Death in Heart Failure
rial) (35). Surgical ventricular reconstruction surgery did
ot improve quality of life when compared with coronary
rtery bypass graft surgery (CABG) in the STICH (Surgical
reatment of Ischemic Heart Failure) randomized trial and
as significantly more costly (36).
inancial Incentives
conomic incentives are designed to alter the behavior of
atients and physicians. Some recent studies show that even
elatively small amounts of money might be surprisingly
nfluential. Doshi et al. (37) used data from the Philadelphia
A Medical Center to assess the effect of increasing
opayments for prescription drugs from $2 to $7. Adher-
nce to statins dropped much more among patients whose
opayments were increased (19% vs. 12%), and they
ere 2 to 3 times as likely to have a prolonged gap in statin
se. Although the copayment was relatively small, it had a
arge impact upon the behavior of these low-income pa-
ients. Solomon et al. (38) found a similar effect of copay-
ents on the use of pharmacotherapy among patients with
ewly diagnosed hypertension, hyperlipidemia, or diabetes.
Some of the most intriguing data on the effect of financial
ncentives on behavior came from a workplace program in
hich smokers were randomized to receive $100 for com-
leting a smoking cessation program, an additional $250 for
roven abstinence within the first 6 months, and $400 more
or an additional 6 months of abstinence. Smoking cessation
as significantly greater at 1 year (15% vs. 5%, p  0.001)
n the group given financial incentives (39).
Pay-for-performance programs have been used to encour-
ge physicians to improve the quality of care, particularly in
he United Kingdom. The potential of these programs to
xacerbate disparities has been a concern, but recent data on
he delivery of primary care services suggests that general
ractitioners in relatively poor areas increased quality of care
o a greater extent than more well-to-do areas and narrowed
he gap in quality measures among regions (40).
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Year in Health Services Research and Outcomes December 15/22, 2009:2343–51ealth Policy
linical practice guidelines aim to improve the quality of
ealth care and should ideally be based on evidence rather
han the opinions of experts. Several years ago, the Amer-
can College of Cardiology/American Heart Association
ACC/AHA) joint practice guidelines began to grade the
evel of evidence supporting their practice recommenda-
ions. A recent analysis (41) demonstrated that, despite the
arge number of clinical trials conducted in cardiovascular
edicine, ACC/AHA Class I recommendations were twice
s likely to be based on expert opinion (37%) than on strong
vidence from multiple randomized trials (19%). This study
uggests that our current system of clinical trials, which
elies mostly on industry-funded studies, does not provide
he evidence most needed to guide clinical management of
ommon cardiovascular conditions.
Coronary bypass surgery, one of the most common major
rocedures in the U.S., has been a prominent focus of many
ealth policy studies. Despite concerns about overuse of
ABG, most (87%) bypass surgery in Northern New
ngland in 2004 and 2005 was found to be appropriate,
eeting Class I indications from the ACC/AHA guidelines
42). The quality of care for CABG has been assessed with
variety of measures. Among 114,233 Medicare patients
ho were discharged alive after CABG, each major post-
perative complication increased hospital costs by 50%
elative to those without complications (43). Outlier pay-
ents for CABG in Medicare, which are typically due to
rocedural complications, dropped substantially from 2000
o 2006 but still varied significantly across U.S. hospitals,
uggesting that there is still variation in quality of care for
ABG (44). Risk-adjusted procedural mortality rates have
een publicly reported in several states as a way to improve
uality and inform consumers, but Shahian and Normand
45) suggest that these measures are flawed when comparing
ospital outcomes. Guru et al. (46) found no correlation
etween the risk-adjusted mortality rate and the proportion
f “preventable deaths” after CABG. Process measures, such
s the use of aspirin, beta-blockers, and prophylactic anti-
iotics, might be better predictors of CABG outcomes than
rocedure volume (47).
Percutaneous coronary intervention (PCI) has received
omewhat less attention from health policy analysts than
ABG, but this might be changing as PCI volumes
ontinue to grow while CABG volumes decline. A report
rom the National Cardiovascular Data Registry (NCDR)
ndicates that PCI conducted at hospitals without cardiac
urgery seem to be as safe as PCIs performed at hospitals
ith cardiac surgery programs (48); emergency CABG was
nfrequent in both settings. Less than 5% of NCDR PCI
rograms routinely monitor cardiac markers after PCI
rocedures (49), even though procedural MI is arguably an
mportant measure of quality of care in this setting. Percuta-
eous coronary intervention procedural mortality can be as-
essed in all programs but is clearly a crude and insensitive teasure of quality of care. Hospital mortality during primary
CI for AMI was lower in higher-volume hospitals and
mong higher-volume operators in New York State (50).
dherence
erhaps the most challenging aspect of quality-of-care
mprovement is patient adherence to recommended treat-
ents. Several recent studies examined the impact on
utcomes of nonadherence to evidence-based drug treat-
ents. Ho et al. (51) found that nonadherence (propor-
ion of days covered80%) to cardioprotective medications
as quite common: 22% for angiotensin-converting enzyme
ACE) inhibitors, 26% for statins, and 29% for beta-
lockers. Better adherence to these medications was associ-
ted with better survival and fewer hospital stays for heart
isease. Daskalopoulou et al. (52) examined treatment of
atients with an AMI with data from general practices in
he United Kingdom. Compared with patients who never
sed statins, those who started statin therapy or continued
se after MI had significantly improved survival (odds ratio:
.72 and 0.84, respectively), whereas those who stopped
tatins had worse survival (odds ratio: 1.88). A similar study
rom Israel by Shalev et al. (53) found that patients enrolled
n a health maintenance organization who were adherent to
tatins (defined as 90% of proportion of days covered),
ad 45% lower mortality compared with patients who were
ot adherent (10% of days covered), with a significant
ose–response relationship between the proportion of days
overed with statins and mortality.
The evidence is mixed as to whether adherence to
ecommended treatments is only associated with better
utcomes or actually has a cause and effect relationship. Ho
t al. (51) found that adherence to statins improved out-
omes but not adherence to proton pump inhibitors or H2
ntagonists. In the study by Daskalopoulou et al. (52),
dherence to statins, aspirin, and proton pump inhibitors
ere all associated with improved survival in unadjusted
nalyses, but only adherence to statins was significantly
ssociated with subsequent outcome after adjustment for
atient characteristics. But, in a fascinating study by Dor-
uth et al. (54) from British Columbia, patients adherent to
tatins were more likely to seek preventive services, less
ikely to have drug dependency, and less likely to have
utomobile accidents than those nonadherent to statins,
uggesting that adherence might simply identify patients
ith generally healthier behaviors.
Assessment of adherence is potentially important for
etermining the appropriate response to poorly controlled
hronic diseases. In a study of VA patients with poorly
ontrolled hypertension, providers intensified treatment ap-
roximately one-third of the time, a value that was no
ifferent for those with high and poor adherence (55).
hese data suggest that providers were not addressing
dherence when making decisions about intensification of
herapy.
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he process of improving quality is often separated into
everal steps, beginning with a description of current care,
ollowed by determining “risk factors” for poor care, creating
nd implementing interventions to improve care, and finally
ocumenting whether outcomes are actually improved.
uring the past year numerous studies have examined this
pectrum of quality-of-care research.
Time to reperfusion has been increasingly used as a
easure of quality of care for AMI. Gibson et al. (56)
sed National Registry of Myocardial Infarction (NRMI)
ata to show that the median door-to-needle time
or thrombolysis decreased from 59 min in 1990 to 29
in in 2006 and that door-to-balloon (D2B) time for
rimary PCI decreased from 111 min in 1994 to 79 min
n 2006. Mehta et al. (57) found a similar improvement
n median D2B times in data from the AHA’s Get With
he Guidelines Program: from 108 min (in 2002) to 82
in (in 2006). Despite these improvements, only 45% of
atients met the recommended D2B time of 90 min.
ing et al. (58) used data from NRMI to demonstrate
hat patients with long waits to presentation were less
ikely to receive timely reperfusion (e.g., longer door-to-
eedle time and lower reperfusion overall) than patients
resenting early after the onset of chest pain. Dorsch et
l. (59) from the United Kingdom found that direct
dmission to the catheterization laboratory from the
mbulance improved attainment of the 90-min goal for
2B from 29% to 94%.
Increased age had an adverse effect on quality of care in
everal recent studies. In the GRACE (Global Registry
f Acute Coronary Events) registry, patients over the age
f 90 years had significantly less use of aspirin (91% vs.
7%) and beta-blockers (80% vs. 87%) (60) than patients
0 years of age or younger. A similar effect of age on drug
se was found among heart failure patients, with 79%
CE inhibitor use for patients age 85 years versus 82%
or age 65 years in the Get With The Guidelines
atabase (61). Older patients were less likely to receive
ppropriate cardiac resynchronization therapy (62), as
ere black patients (odds ratio: 0.45; 95% confidence
nterval: 0.36 to 0.57), those in the Northeast U.S., and
hose with greater left ventricular ejection fractions.
chiele et al. (63) found increasing rates over time of
ecommended care for elderly patients with AMI, which
xplained much of the large drop in mortality for ST-
egment elevation MI.
Health system factors have also been associated with
uality of care in recent investigations. Patients with
eart failure and “do not resuscitate” orders but without
ther indications that care was limited were less likely to
eceive an assessment of left ventricular ejection fraction,
CE inhibitors, and anticoagulation when indicated64). Timing of hospital admission was found to affect ouality of care in several studies. Patients with an AMI
ho arrived outside of regular working hours were less
ikely to receive primary PCI and had longer D2B times
65). Patients with pulmonary embolism had higher
ortality when admitted over the weekend than during
he work week (66). Although this might indicate poorer
are during the weekend, it is difficult to completely
ontrol for differences in illness severity that might exist
etween those admitted during on hours and those
dmitted during off hours.
Although quality of care is important to patients, they
ight be unable to judge the quality of care they receive.
ee et al. (67) that found that patient satisfaction with their
are had no relationship to guideline-recommended care for
atients with AMI. Satisfied patients were more likely to be
lder and to have better physical function and less likely to
ave depression.
Specialty training might affect clinical outcomes in cer-
ain conditions. Curtis et al. (68) found that physicians
ithout formal training in cardiology who implanted ICDs
ad the highest rate of procedural complications, whereas
hysicians with training in electrophysiology had the lowest
ate of complications. Karamlou et al. (69) found that
atients with congenital heart disease who were operated
pon by pediatric heart surgeons (defined as those whose
ase mix was at least 75% pediatric heart procedures) had
ower in-hospital mortality than those operated upon by
ther surgeons.
Several studies have evaluated interventions to improve
he quality cardiac care for hospitalized patients. Hospi-
als enrolled in the Get With The Guidelines Stroke
rogram demonstrated significant improvement in 7
ndividual measures and 1 composite measure over 5 years
70). The improvements in stroke care were seen in all
ospitals, regardless of size, geography, and teaching
tatus. Brush et al. (71) compared a 29-hospital collab-
rative to improve care for AMI and heart failure with a
roup of control hospitals. Hospitals in the collaborative
ad higher quality-of-care measures than noncollabora-
ive hospitals at study entry, but both groups improved on
uality measures to a similar extent over follow-up.
iazza et al. (72) randomized attending physicians to a
eminder by a staff member to use prophylaxis for venous
hromboembolism; patients whose attending physician
eceived the reminder were twice as likely to receive
rophylaxis and had a nonsignificant trend toward re-
uced symptomatic thromboembolism.
Two reports provided insight by combining results of
ultiple programs. In a summary of 15 randomized trials
f care-coordination for Medicare patients with chronic
iseases including heart failure and coronary artery dis-
ase, Peikes et al. (73) reported that overall there was no
lear cost savings from these programs. However, those
rograms that focused on the transition from inpatient to
utpatient care and those with substantial in-person
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eutral and lead to care improvements. A meta-analysis
y Auer et al. (74) of 14 in-hospital programs to improve
econdary prevention for ischemic heart disease reported
hat uncontrolled studies demonstrated a much larger
enefit than controlled studies. Interventions that only
ocused on the patient and did not impact providers or
he health care system were unsuccessful. Taken together,
hese reports indicate that improved quality and cost
avings are difficult to achieve and that the benefit and
ost reduction of any one program might be overstated in
tudies that are not randomized.
isparities
acial disparities have continued to be documented over
he past year. In an analysis of 20-year follow-up of the
ARDIA (Coronary Artery Risk Development in Young
dults) study, Bibbins-Domingo et al. (75) found that
lack patients have a significantly higher incidence of
eart failure before the age of 50 years (0.9% to 1.1%)
han white patients (0% to 0.08%, p  0.0001). Patients
ho developed heart failure were more likely to have
rior hypertension, obesity, and reduced left ventricular
ysfunction indicating potential targets for prevention
nd screening. Shaw et al. (76), with data from the
CDR, found that black patients and women were less
ikely to have significant disease at coronary angiography
han white men, suggesting that physicians might be
ore selective in their referral of white male patients. In
nother study, black and Hispanic patients were more
ikely to be referred to cardiologists for coronary artery
isease than white patients but had fewer follow-up
onsultations (77). Compared with white patients, black
atients with coronary heart disease had lower quality of
ife (78), were more likely to receive evidence-based
edications (79), were less likely to receive discharge
nstructions and tobacco counseling (79), and were less
ikely to be treated for depression (80). Among U.S.
edicare beneficiaries, short-term mortality for AMI
ecreased significantly in all racial groups but decreased
aster for whites than for blacks (81). With a registry of
atients with myocardial infarction, Spertus et al. (82)
howed that the higher rates of mortality, repeat hospital
tay, and angina and the lower quality of life for blacks
ompared with whites was largely explained by differ-
nces in patient characteristics and site of care. Black
atients hospitalized emergently for heart failure were
ounger, less severely ill on admission, and less likely to
xperience short-term fatal and nonfatal outcomes than
hite patients (83).
One hypothesis for the observed poorer outcomes in
lack compared with white patients has been racial discrim-
nation leading to increased stress and progression of ath-
rosclerosis. Albert et al. (84) found in the Dallas Heart ctudy that black patients who reported discrimination were
ore likely to be college graduates, to have a family history
f myocardial infarction, and to be more physically active
han black patients who did not report discrimination (each
 0.05). However, they found no association between
eports of discrimination and aortic wall thickness, aortic
laque area, prevalent coronary artery calcification, or ele-
ated C-reactive protein for different ethnic groups.
Sex differences have been the focus of many studies of
eart disease during the past year. When compared with
en, women with coronary artery disease showed similar
eclines in mortality (81), and women with acute coronary
yndromes had fewer high-risk angiographic features, were
ess likely to receive aspirin or glycoprotein IIb/IIIa inhib-
tors, and were less often discharged on aspirin or statin
85). Women had similar in-hospital acute coronary syn-
rome mortality but higher rates of cardiogenic shock, heart
ailure, any bleeding, and any vascular complications (85).
owever, another study of patients with AMI found no sex
ifferences in the prescription of aspirin, beta-blockers,
CE inhibitors, or angiotensin receptor blockers (86).
onsistent with prior studies, women were 46% less likely
han men to undergo coronary angiography but had similar
ates of revascularization (86). Interestingly, subacute stent
hrombosis was found to be less in women compared with
en (85). Women undergoing ICD insertion were more
ikely to have procedural complications than men (87), but
ffectiveness of the ICD seemed to be similar (84). Women
ith heart failure had similar rates of use of ACE inhibitors,
ngiotensin receptor blockers, beta-blockers, aldosterone
nhibitors, and cardiac resynchronization therapy as men but
ignificantly less use of ICDs, anticoagulation therapy for
trial fibrillation, and education for heart failure (88).
Although many studies have documented the existence
f disparities, only a few studies have tested interventions
o reduce racial and sex differences in care. Implementa-
ion of a financial reward system in the United Kingdom
as associated with a larger improvement in quality of
are in poor areas with a higher minority population,
eading to a narrowing of the wealthy–poor (and white–
onwhite) disparity in the quality of care (37). In a study
rom Israel, Novack et al. (89) found that female sex was
o longer a significant risk factor for mortality after
mplementation of the 2000 European and American
uidelines for Acute Coronary Syndromes. McWilliams
t al. (90) examined trends in risk factors for coronary
rtery disease in the U.S. from 1996 to 2000 and found
hat, although all racial groups improved, differences in
isk factor control persisted. The one exception was for
atients enrolled in Medicare, where racial differences
ere smaller. These studies indicate that quality im-
rovement strategies and programs targeted at all patients
an have the impact of narrowing absolute differences in
are between different groups.
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